Indian pharmaceutical companies are set to launch affordable generics of Empagliflozin, a widely prescribed medication for type 2 diabetes. Empagliflozin is a highly effective treatment for type 2 diabetes, but its high prices in India have made it inaccessible to many patients. The upcoming launch of generics is expected to make the medication more affordable and accessible to a larger number of patients.
Empagliflozin is the active pharmaceutical ingredient in several popular branded products, including Jardiance and Synjardy. It is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor that helps the kidneys to filter out excess sugar from the blood, reducing the risk of complications associated with type 2 diabetes. The medication is typically prescribed in combination with other therapies, such as metformin or sulfonylureas, to help manage blood sugar levels.
Indian generic pharmaceutical companies, including Dr. Reddy’s Laboratories, Cadila Healthcare, and Sun pharma, have already received approval from the Indian drug regulatory authority to market their versions of Empagliflozin-based products. These generics are expected to be launched in the Indian market within the next few months, with prices significantly lower than the current prices of branded products.
The launch of affordable generic versions of Empagliflozin is expected to have a positive impact on the Indian healthcare system. Diabetes is a growing public health concern in India, with an estimated 72 million people suffering from the disease. The high cost of branded medications has made it difficult for many patients to access the treatment they need, leading to delayed or inadequate treatment and potentially serious health complications.
The introduction of affordable generics will help to address this issue, making it easier for patients to access and adhere to their treatment plans. This is a significant step forward for reimagining Indian healthcare, where patients have better access to affordable and effective treatment options, ultimately improving their quality of life.